Table 1.
Demographic and clinical parameters of the two groups.
| AD (n = 30) | NC (n = 30) | t/χ2 | p Value | |
|---|---|---|---|---|
| Age (years) | 65.17 ± 11.34 | 65.63 ± 7.08 | 0.246 | 0.620 |
| Female (%) | 14 (46.67%) | 13 (43.33%) | 0.067 | 0.795 |
| Education (years) | 9.07 ± 4.08 | 8.47 ± 3.15 | 0.346 | 0.557 |
| Diabetes (%) | 9 (30.0%) | 8 (26.67%) | 8.208 | 0.774 |
| Hypertension (%) | 11 (36.67%) | 10 (33.33%) | 7.326 | 0.786 |
| MMSE | 18.17 ± 6.10 | 26.43 ± 1.63 | 35.101 | <0.001 |
| MoCA | 13.93 ± 5.27 | 23.70 ± 2.73 | 38.823 | <0.001 |
| CDT | 19.96 ± 4.56 | 24.78 ± 2.61 | 116.43 | <0.001 |
| CDR | 1.15 ± 0.51 | 0.00 ± 0.00 | - | - |
| CSF Aβ42 (pg/mL) | 452.99 ± 101.25 | 1062.29 ± 101.25 | −5.495 | <0.001 |
| CSF Aβ40 (pg/mL) | 9902.66 ± 2431.47 | 12,280.38 ± 1904.07 | −2.513 | 0.021 |
| CSF Aβ42/Aβ40 | 0.047 ± 0.011 | 0.086 ± 0.019 | −6.029 | <0.001 |
| CSF t-tau (pg/mL) | 413.27 ± 166.92 | 81.27 ± 82.79 | 5.714 | <0.001 |
| CSF p-tau (pg/mL) | 195.1 ± 233.98 | 42.86 ± 16.13 | 2.045 | 0.054 |
| APOE genotype group | 3.314 | 0.191 | ||
| E2 | 7 (23.3%) | 13 (43.3%) | ||
| E3 | 12 (40.0%) | 11 (36.7%) | ||
| E4 | 11 (36.7%) | 6 (20.0%) |
Notes: Data are given as means ± SD or percentages. Twelve AD patients and ten controls underwent lumbar puncture, and the typical CSF Aβ42, Aβ40, t-tau, and p-tau were tested. There is no e2e4 genotype in this study. Abbreviations: AD, Alzheimer’s disease; NC, normal cognition healthy controls. MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; CDT, clock drawing test; CDR, Clinical Dementia Rating; CSF, Cerebrospinal fluid; APOE, Apolipoprotein E. SD, standard deviation. APOE genotype group defined as E2 = e2e2 or e2e3; E3 = e3e3; and E4 = e3e4 or e4e4.